Regulatory

Vesalio Expands International Neurovascular Portfolio with CE Mark of NeVa VS and NeVa 3.0 mm and Receives Additional FDA 510(k) Clearance for its Aspiration Catheters

Company advances global neuro-intervention footprint with new CE-marked devices for vasospasm and stroke, and expanded U.S. indications for aspiration catheters. PLANO, Texas, Feb. 10, 2026 /PRNewswire/ — Vesalio, a global leader in vascular intervention, today announced CE Mark…

AliveCor Announces FDA Clearance of New Cardiac Determinations for Kardia 12L ECG System, Bringing Total to 39

KAI 12L, the AI powering Kardia 12L, adds five new detections to further expand diagnostic capabilities for the world’s first handheld 12-lead ECG with a unique single-cable design. KAI 12L, the AI powering Kardia 12L, adds five new detections to further expand diagnostic capabilities for the world’s first handheld 12-lead ECG with a unique single-cable design.

RAMPART Launches SECURE Clinical Program to Advance Clinical Evidence for Next Generation Radiation Protection

BIRMINGHAM, Ala. — January 8, 2025 — Rampart, a Birmingham, Alabama–based medical device company redefining interventional radiation safety, today announced the launch of the SECURE Clinical Program, Studies Evaluating Clinical Utility of Radiation mitigation Equipment, a first-of-its-kind, multi-specialty clinical initiative designed to further advance the scientific evidence for next-generation radiation […]

Shape Memory Medical Secures EU MDR Certification for IMPEDE® Embolization Plug Product Family, Accelerating Global Innovation in Vascular Care

SAN JOSE, Calif.–(BUSINESS WIRE)–Shape Memory Medical Inc., innovator of the proprietary shape memory polymer technology for endovascular applications, announced that its IMPEDE® Embolization Plug product family has received certification as a Class III device under the European Union (EU) Medical Device Regulation (MDR) 2017/745. The IMPEDE Embolization Plug family, previously […]

Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation

HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for the Company’s Investigational Device Exemption (IDE), allowing Pulse Biosciences to […]

HeartSciences Announces FDA 510(k) Submission for MyoVista® wavECG™ Device

Southlake, TX, Dec. 15, 2025 (GLOBE NEWSWIRE) — HeartSciences Inc.  (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company advancing the use of ECG/EKGs through the integration of artificial intelligence (“AI”), today announced it has submitted its MyoVista® wavECG™ device to the U.S. Food and Drug Administration (“FDA”) for 510(k) premarket clearance.